A Phase 4 interventional study of fecal microbiota transplant in Microbial Colonization, Bacterial Peritonitis and Faeces Smearing, sponsored by Centre d'Investigation Clinique et Technologique 805. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-27.
Sponsored by Centre d'Investigation Clinique et Technologique 805 · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Communicable Diseases with a site in France — 16 open to participants now, 16 under way, 2 of them phase 3. Communicable Diseases · France.
Among the 42 studies in Communicable Diseases with a site in France, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2014, is one of 2 in phase 4, and was the 6th registered.
628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.
Browse Communicable Diseases studies →16 of the 42 studies in Communicable Diseases with a site in France are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in France, United States, Canada and 3 more countries
Ages 18–65
ANRS, Emerging Infectious Diseases · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages up to 16
University of Minnesota · Sites in France, United States, Argentina and 18 more countries
Ages 18+
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+ · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 89 across 381 interventional studies indexed under Communicable Diseases.
Median enrollment 75 across the 11 interventional studies, 334 across the 31 observational. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 42 have an industry lead sponsor. The 10 most frequent:
Centre d'Investigation Clinique et Technologique 805 is the lead sponsor of 75 studies on the registry; 2 are open to participants now.
Centre d'Investigation Clinique et Technologique 805 has 1 study filed under Communicable Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Communicable Diseases with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05903352Phase 3Assistance Publique - Hôpitaux de ParisCustomized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia | 2027-05 |
| NCT05814237European Clinical Research Alliance for Infectious Diseases (ECRAID)POS-ARI-ER Observational Study of Acute Respiratory Infections | 2027-02-28 |
| NCT06893757ANRS, Emerging Infectious DiseasesProspective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB) | 2027-06 |
| NCT06024421Institut National de la Santé Et de la Recherche Médicale, FranceEvaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers | 2027-06 |
| NCT07069400University of MinnesotaAn International Observational Study of Adults With Acute Infection | 2027-06-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 42 studies in Communicable Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Our trial try to eradicate digestive tract colonization of patient harboring Extreme Drug Resistant (XDR) bacteria by performing a fecal transplantation.
Main objective:
Evaluate the eradication of the colonization of patient harboring XDR bacteria after a fecal transplantation from a healthy donor.
Secondary objectives:
English Evaluate the side effects of this procedure and tolerability. Evaluate the efficacy of the transplant if the patient is harboring glycopeptid resistant enteroccus (GRE) or carbapenem resistant enterobacteriae (CRE)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient will be transplanted with a healthy donor microbiota, free from XDR bacteria, in order to evaluate the impact on the digestive tract colonization Whole process of feces screening and reconstitution was under the responsibility of the pharmacists in charge of the study. Patient will benefit of a naso-duodenal tube in order to perform a bowel lavage prio to the fecal microbiota transplant. Patient will be monitored for 24h to rule out potential adverse events.
Drug: fecal microbiota transplant
We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
Also known as: FEDEX
Negativation of digestive tract colonization
Negativation of the rectal swab performed, free from CRE or GRE
Time frame: At one week, 2 weeks, one month up to 6 months
Metagenomics profile between donor and recipient depending on decolonization
Study with a universal super donor in order to improve efficacy
Time frame: At one week, 2 weeks, one month up to 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2014 to primary completion in Dec 2020, 73 months.
Of 13 phase 4 interventional studies under Communicable Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 65. This study's 73 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fecal microbiota
Centre d'Investigation Clinique et Technologique 805